translocations or amplifications in addition to the genomic alterations already existing in the first CLL, but deficiency the typical mutations observed in Most important DLBCL indicating that they might correspond to a special biological group.Unfit patients even have the choice of venetoclax furthermore obinutuzumab (VO) as frontline therapy. Thi